Brentuximab vedotin in the treatment of CD30+ PTCL.

Authors

• Stefan K Barta
• Jerald Z Gong
• Pierluigi Porcu

Publication/Presentation Date

12-26-2019

Abstract

The development of brentuximab vedotin has opened a new era in the management of peripheral T-cell lymphomas (PTCLs). The improved outcomes with brentuximab vedotin (BV) in combination with cyclophosphamide, doxorubicin, and prednisone (BV-CHP) vs cyclophosphamide, doxorubicin, vincristine, and prednisone in the ECHELON-2 trial are practice changing for common nodal CD30+ PTCLs. Questions regarding the optimal cutoff of CD30 expression for BV-CHP therapy and the efficacy and safety of BV-CHP in less common subtypes of CD30+ PTCL subtypes await clarification.

Volume

134

Issue

26

First Page

2339

Last Page

2345

ISSN

1528-0020

Published In/Presented At

Barta, S. K., Gong, J. Z., & Porcu, P. (2019). Brentuximab vedotin in the treatment of CD30+ PTCL. Blood, 134(26), 2339–2345. https://doi.org/10.1182/blood.2019001821

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

31697814

Department(s)

Administration and Leadership

Document Type

Article